docetaxel + cisplatin + fluorouracil (Cancer Hospital of Guangxi Medical University)

**Docetaxel + cisplatin + fluorouracil** is a three-agent intravenous induction chemotherapy regimen, commonly called **TPF**, evaluated by Cancer Hospital of Guangxi Medical University for locally advanced nasopharyngeal carcinoma before concurrent chemoradiotherapy. Docetaxel disrupts the microtubule network required for cellular division, cisplatin forms cytotoxic intra- and interstrand DNA cross-links, and fluorouracil is a fluoropyrimidine antimetabolite that inhibits thymidylate synthase and disrupts nucleic-acid synthesis. The registered randomized Phase II study compared TPF induction chemotherapy with gemcitabine + cisplatin induction chemotherapy in locally advanced nasopharyngeal carcinoma. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02016417))

Brand names

TaxoterePlatinolAdrucil

Other names

DCFDCF regimenTPFTPF regimen